Prior Huntington’s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear.
Objective:
Describe ancillary service utilization in a cohort of individuals with HD and determine which participant characteristics are associated with ancillary service utilization.
Methods:
Retrospective cross-sectional analysis of Enroll-HD database. Participants were grouped by therapy: physical and/or occupational (PT/OT), psychotherapy and/or counseling (PC), speech and/or swallowing (ST). We performed bivariate comparisons analysis of demographic and disease characteristics between those with/without each therapy and to analyze one-year mean change in assessment scores.
Results:
Of 4751 participants, 1537 (32.35%) utilized therapies (11.82% PT/OT, 5.33% PC, 3.01% ST, 1.98% all three, 10.21% two therapies). PT/OT participants had worse motor and functional scores: mean UHDRS motor score (41.17 vs. 38.05, p = 0.002), median total functional capacity score (TFC) (8.00 vs. 9.00, p < 0.001). PC participants had worse mood but better cognitive and functional scores: median depression score (7.00 vs. 2.00, p < 0.001), median MMSE (28.00 vs. 26.00, p < 0.001), median TFC (10.00 vs. 8.00, p < 0.001). ST participants had more dysarthria, and worse cognitive and functional scores: dysarthria (32.2% vs. 20.1% p < 0.001), mean correct Symbol Digit Modality Test (16.79 vs. 23.27, p < 0.001), median TFC (6.00 vs. 9.00, p < 0.001). Over one year, PC participants’ depression scores improved compared to untreated (– 1.24 vs. – 0.11, p = 0.040). ST participants’ depression scores worsened (1.14 vs. – 0.23, p = 0.044). Mean change in TFC was not significant for any therapies.
Conclusions:
Only 32% of Enroll-HD site participants received ancillary services. Use correlated with expected clinical characteristics, though impact of use remains unclear.
HeemskerkAW, RoosRA. Aspiration pneumonia and death in Huntington’s disease. PLoS Curr. 2012; 4: Rrn1293. doi:10.1371/currents.RRN1293.
3.
FrankS. Treatment of Huntington’s disease. Neurotherapeutics. 2010; 11(1): 153–60. doi:10.1007/s13311-013-0244-z.
4.
BilneyB, MorrisME, PerryA. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington’s disease: a systematic review. Neurorehabil Neural Repair. 2003; 17(1): 12–24. doi:10.1177/0888439002250448.
5.
MestreTA, FerreiraJJ. An evidence-based approach in the treatment of Huntington’s disease. Parkinsonism Relat Disord. 201218(4): 316–20. doi:10.1016/j.parkreldis.2011.10.021.
ThompsonJA, CruickshankTM, PenaililloLE, LeeJW, NewtonRU, BarkerRA, et al., The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington’s disease: a pilot study. Eur J Neurol. 2013; 20(9): 1325–9. doi:10.1111/ene.12053.
8.
CruickshankTM, ReyesAP, PenaililloLE, PulverentiT, BartlettDM, ZaenkerP, et al., Effects of multidisciplinary therapy on physical function in Huntington’s disease. Acta Neurol Scand. 2018; 138(6): 500–507. doi:10.1111/ane.13002.
9.
PiiraA, van WalsemMR, MikalsenG, NilsenKH, KnutsenS, FrichJC. Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington’s disease: a prospective intervention study. PLoS Curr. 2013; 5. doi:10.1371/currents.hd.9504af71e0d1f87830c25c394be47027.
10.
PiiraA, van WalsemMR, MikalsenG, OieL, FrichJC, KnutsenS. Effects of a two-year intensive multidisciplinary rehabilitation program for patients with Huntington’s disease: a prospective intervention study. PLoS Curr. 2014; 6. doi:10.1371/currents.hd.2c56ceef7f9f8e239a59ecf2d94cddac.
11.
van WalsemMR, PiiraA, MikalsenG, FossmoHL, HoweEI, KnutsenSF, et al., Cognitive performance after a one-year multidisciplinary intensive rehabilitation program for Huntington’s disease: an observational study. J Huntingtons Dis. 2018; 7(4): 379–89. doi:10.3233/jhd-180294.
12.
CruickshankTM, ThompsonJA, DominguezDJ, ReyesAP, ByneveltM, Georgiou-KaristianisN, et al., The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: an exploratory study. Brain Behav. 2015; 5(2): e00312. doi:10.1002/brb3.312.
13.
ZinziP, SalmasoD, De GrandisR, GrazianiG, MaceroniS, BentivoglioA, et al., Effects of an intensive rehabilitation programme on patients with Huntington’s disease: a pilot study. Clin Rehabil. 2007; 21(7); 603–13. doi:10.1177/0269215507075495.
14.
FritzNE, RaoAK, KegelmeyerD, KloosA, BusseM, HartelL, et al., Physical therapy and exercise interventions in Huntington’s disease: a mixed methods systematic review. J Huntingtons Dis. 2017; 6(3): 217–35. doi:10.3233/jhd-170260.
15.
QuinnL, HamanaK, KelsonM, DawesH, CollettJ, TownsonJ, et al., A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism Relat Disord. 2016; 31:46–52. doi:10.1016/j.parkreldis.2016.06.023.
16.
KhalilH, QuinnL, van DeursenR, DawesH, PlayleR, RosserA, et al., What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study. ClinRehabil. 2013; 27(7): 646–58. doi:10.1177/0269215512473762.
17.
BusseM, QuinnL, DebonoK, JonesK, CollettJ, PlayleR, et al., A randomized feasibility study of a 12-week community-based exercise program for people with Huntington’s disease. J Neurol Phys Ther. 2013; 37(4): 149–58. doi:10.1097/npt.0000000000000016.
BusseM, Al-MadfaiDH, KenkreJ, LandwehrmeyerGB, BentivoglioA, RosserA. Utilisation of healthcare and associated services in Huntington’s disease: a data mining study. PLoS Curr. 2011; 3: Rrn1206. doi:10.1371/currents.RRN1206.
21.
ShakespeareJ, AndersonJ. Huntington’s disease–falling through the net. Health Trends. 1993; 25(1), 19–23.
22.
SkirtonH, GlendinningN. Using research to develop care for patients with Huntington’s disease. Br J Nurs. 1997; 6(2): 83–90. doi:10.12968/bjon.1997.6.2.83.
23.
Enroll-HD. A worldwide observational study for Huntington’s disease families. Dataset Cutoff December. 2016. http://www.enroll-hd.org.
24.
LandwehrmeyerGB, Fitzer-AttasCJ, GiulianoJD, GonçalvesN, AndersonKE, CardosoF, et al., Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease. Mov Disord Clin Pract. 2017; 4(2): 212–24. doi:10.1002/mdc3.12388.
HamiltonA, FermU, HeemskerkA-W, Twiston-DaviesR, MathesonKY, SimpsonSA, et al., Management of speech, language and communication difficulties in Huntington’s disease. Neurodegener Dis Manag. 2012; 2(1): 67–77. doi:10.2217/nmt.11.78.
30.
QuinnL, BusseM. Development of physiotherapy guidance and treatment-based classifications for people with Huntington’s disease. Neurodegener Dis Manag. 2012; 2(1): 11–9. doi:10.2217/nmt.11.67.
31.
KvamS, KleppeCL, NordhusIH, HovlandA. Exercise as a treatment for depression: A meta-analysis. J Affect Disord. 2016; 202: 67–86. doi:10.1016/j.jad.2016.03.063.
32.
CarreiraK, MillerMD, FrankE, HouckPR, MorseJQ, DewMA, et al., A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function. Int J Geriatr Psychiatry. 2008; 23(11): 1110–3. doi:10.1002/gps.2031.
33.
ChestonR, IvaneckaA. Individual and group psychotherapy with people diagnosed with dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2017; 32(1): 3–31. doi:10.1002/gps.4529.
34.
BeydounMA, BeydounHA, GamaldoAA, TeelA, ZondermanAB, WangY. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014; 14: 643. doi:10.1186/1471-2458-14-643.
35.
EllisT, KatzDI, WhiteDK, DePieroTJ, HohlerAD, Saint-HilaireM. Effectiveness of an inpatient multidisciplinary rehabilitation program for people with Parkinson disease. Phys Ther. 2008; 88(7): 812–9. doi:10.2522/ptj.20070265.
36.
TrendP, KayeJ, GageH, OwenC, WadeD. Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carers. Clin Rehabil. 2002; 16(7): 717–25. doi:10.1191/0269215502cr545oa.
37.
WadeDT, GageH, OwenC, TrendP, GrossmithC, KayeJ. Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2003; 74(2): 158–62. doi:.
38.
Metzler-BaddeleyC, CanteraJ, CoulthardE, RosserA, JonesDK, BaddeleyRJ. Improved executive function and callosal white matter microstructure after rhythm exercise in Huntington’s disease. J Huntingtons Dis. 2014; 3(3): 273–83. doi:10.3233/jhd-140113.
39.
HocklyE, CorderyPM, WoodmanB, MahalA, van DellenA, BlakemoreC, et al., Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice. Ann Neurol. 2002; 51(2): 235–42. doi:.
40.
SpiresTL, GroteHE, VarshneyNK, CorderyPM, van DellenA, BlakemoreC, et al., Environmental enrichment rescues protein deficits in a mouse model of Huntington’s disease, indicating a possible disease mechanism. J Neurosci. 2004; 24(9): 2270–6. doi:10.1523/jneurosci.1658-03.2004.
41.
van PraagH, KempermannG, GageFH. Neural consequences of environmental enrichment. Nat RevNeurosci. 2000; 1(3): 191–8. doi:10.1038/35044558.
42.
LazicSE, GroteHE, BlakemoreC, HannanAJ, van DellenA, PhillipsW, et al., Neurogenesis in the R6/1 transgenic mouse model of Huntington’s disease: effects of environmental enrichment. Eur JNeurosci. 2006; 23(7): 1829–38. doi:10.1111/j.1460-9568.2006.04715.x.
43.
MazarakisNK, MoC, RenoirT, van DellenA, DeaconR, BlakemoreC, et al., ‘Super-enrichment’ reveals dose-dependent therapeutic effects of environmental stimulation in a transgenic mouse model of Huntington’s disease. J Huntingtons Dis. 2014; 3(3): 299–309. doi:10.3233/jhd-140118.
